ghadmin
Patient Choice: A Critical Piece of Shared Decision Making
Colorectal cancer (CRC) is a leading cause of cancer death in the United States. However, it is also one of the most preventable and treatable cancers if detected early through screening
The Power Within
Guardant Health Video
5 Misconceptions about CRC
Because of its widespread impact, it is important to be aware of some key facts – and misconceptions. Here are 5 common misconceptions about this cancer.
Unlocking the secrets of cancer in our blood: A founder’s perspective
A Q&A with Helmy Eltoukhy, Ph.D., co-founder, chairman and co-chief executive officer of Guardant Health
Health Equity in Clinical Trials: Patient Navigation Plays an Integral Role
Clinical trials are a critical step in developing new treatments and medications and a crucial tool for evaluating the safety and efficacy of existing treatments.
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
Reimbursement supports expanded access to blood-based comprehensive genomic profiling with Guardant360 CDx for patients with advanced solid tumor cancers and their care teams across Japan
Access to Critical Cancer Screening Tools is At Risk
By now, most Americans have likely heard about the federal court ruling out of Texas regarding access to abortion medication. A second healthcare-related case, also out of Texas, has received less attention, but has the potential to likewise impact healthcare choices for millions of Americans.
Can a Blood Test Screen for Colon Cancer? Guardant Health Chief Medical Officer Shares Promising Update
Currently, there’s a huge push in the cancer community to develop blood tests that can screen for different types of the disease. A company called Guardant Health is working on one of these tools, a test called “Shield” that can screen blood for signs of early-stage colon cancer.
EUCOPE launches the European Coalition for Access to Comprehensive Genomic Profiling (ECGP)
EUCOPE, along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP)
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance